A prospective, randomized, parallel group study analyzing the effect of BTX-A (botox) and nonanimal sourced hyaluronic acid (NASHA, restylane) in combination compared with NASHA (restylane) alone in severe glabellar rhytides in adult female subjects: Treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A

Dermatologic Surgery

Volumn 29, Issue 8, 2003, Pages 802-809

  Carruthers, Jean ^a,b   Carruthers, Alastair ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Carruthers Aesth Facial Opthalmol   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; HYALURONIC ACID DERIVATIVE; NONANIMAL SOURCED HYALURONIC ACID; RESTYLANE; UNCLASSIFIED DRUG;

ADULT; AGING; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; EDEMA; ESTHETICS; FACIAL EXPRESSION; FEMALE; FOREHEAD; HUMAN; MONOTHERAPY; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SKIN;

ADULT; AGED; BOTULINUM TOXIN TYPE A; DRUG THERAPY, COMBINATION; FEMALE; FOREHEAD; HUMANS; HYALURONIC ACID; MIDDLE AGED; PROSPECTIVE STUDIES; SKIN AGING; TREATMENT OUTCOME;

EID: 0043246550     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4725.2003.29212.x     Document Type: Article

References (13)

1. Carruthers A, Carruthers J. Cosmetic uses of botulinum A exotoxin. In: Klein AW, ed. Tissue Augmentation in Clinical Practise. New York: Marcel Dekker, 1998:224-5.
2. National Institutes of Health. NIH Consensus Development Conference on Clinical Use of Botulinum A Exotoxin. Bethesda, MD: U.S. Department of of Health and Human Services, 1990:1-20.
3. Website American Academy of Cosmetic Surgery, www.cosmetic- surgery.org. November, 2000.
4. Carruthers JDA, Carruthers A. Treatment of glabellar frown lines with C botulinum exotoxin. J Dermatol Surg Oncol 1992;18:17-21.
5. American Academy of Dermatology Standardized Photo Classification of Static, Dynamic Glabellar Rhytides Developed for Phase III FDA Trials to Establish a Cosmetic Indication for Glabellar BOTOX Chemodenervation, Allergan Pharmaceuticals, 1999. Presented as a Poster March 10-14, 2000, American Academy of Dermatology meeting, San Francisco, CA, 1999.
6. Pribitkin EA, Greco TM, Goode RL, Keane WM. Patient selection in the treatment of glabellar wrinkles with botulinum type A injection. Arch Otolaryngol Head Neck Surg 1977;123:321-67.
7. Connell BF, Lambros VS, Neurohr GR. The forehead lift: techniques to avoid complications and produce optimum results. Aesth Plast Surg 1989;13:217.
8. McCord CD Jr. Endoscopic forehead lift. In: Eyelid surgery: principles and techniques. New York: Lippincott Raven, 1995:368-79.
9. Ellis DA, Tan AK. Cosmetic upper facial rejuvenation with botulinum. J Otolaryngol 1997;26:92-6.
10. Keen M, Blitzer A, Aviv J, et al. Botulinum Toxin A for Hyperkinetic Facial Lines: Results of a Double Blind, Placebo-Controlled Study. Boca Raton, Florida: American Academy of Facial Plastic and Reconstructive Surgery, 1993.
11. Carruthers J, Carruthers A. The management of glabellar rhytides combining intradermal hylan B with botulinum toxin A injection. Dermatol Surg, 2003;29:539-44.
12. Carruthers A, Carruthers J, Said S. Double-blind, randomized, parallel group, dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Arch Dermatol, in press.
13. Q-MED, Website: info@Q-med.com.